{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:55:41Z","timestamp":1777881341419,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmol Eye Dis"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The loss of central vision plays a major role in the quality of life (QoL). This study evaluates the changes in QoL in the treatment of low-risk neovascular age-related macular degeneration (AMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the changes in vision-related QoL in patients receiving intravitreal ranibizumab loading dose for low-risk neovascular AMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A prospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Forty-two eyes of 42 patients receiving ranibizumab injections for neovascular AMD were included in this prospective study. The changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) of the patients before the treatment, and 1 month after three loading doses were evaluated. Turkish version of the National Eye Institute 25-Item Vision Function Questionnaire (NEI VFQ-25 TR) was conducted. The changes of QoL scores through the NEI VFQ-25 TR questionnaire were compared with visual acuity (VA) and CMT measurements before the injections and 1 month after the loading dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Forty-two patients (19 females and 23 males) were included in the study, and the mean age was 72.69\u2009\u00b1\u20097.12 years. After the treatment, a statistically significant improvement in BCVA (0.98\u2009\u00b1\u20090.44, 0.76\u2009\u00b1\u20090.42 logMAR, p\u2009&lt;\u20090.001) and a significant decrease in CMT (357.90\u2009\u00b1\u200971.71, 274.50\u2009\u00b1\u200958.35 \u03bcm, p\u2009&lt;\u20090.001) was observed. The QoL composite score was found to be statistically significantly higher after the treatment (64.27\u2009\u00b1\u200911.47, 68.56\u2009\u00b1\u200911.39, p\u2009&lt;\u20090.001). General vision ( p\u2009&lt;\u20090.001), ocular pain ( p\u2009=\u20090.025), near activities ( p\u2009&lt;\u20090.001), distance activities ( p\u2009=\u20090.027), vision-specific mental health ( p\u2009=\u20090.014), vision-specific role difficulties ( p\u2009&lt;\u20090.001), and peripheral vision ( p\u2009=\u20090.046) were significantly higher after the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25158414221108021","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T07:24:35Z","timestamp":1658129075000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-3050","authenticated-orcid":false,"given":"Hatice","family":"Daldal","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Usak University, 1 Eylul Yerleskesi, 64200 Usak, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"bibr1-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31550-2"},{"key":"bibr2-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.564"},{"key":"bibr3-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1986.01050170092029"},{"key":"bibr4-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.008"},{"key":"bibr5-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"bibr6-25158414221108021","unstructured":"Age-Related Eye Disease Study Research Group. Age-related macular degeneration to affect 77 million Europeans by 2050. British Medical Journal, 11 November 2019, https:\/\/medicalxpress.com\/news\/2019-11-age-macular-degeneration-affect-million.html"},{"key":"bibr7-25158414221108021","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200422092620"},{"key":"bibr8-25158414221108021","volume":"136","author":"Ferlay J","year":"2014","journal-title":"Int J Cancer"},{"key":"bibr9-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.098426"},{"key":"bibr10-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.11.1496"},{"key":"bibr11-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.7.1050"},{"key":"bibr12-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1080\/09286580590967763"},{"key":"bibr13-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801537"},{"key":"bibr14-25158414221108021","doi-asserted-by":"publisher","DOI":"10.36740\/WLek202103238"},{"key":"bibr15-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12781"},{"key":"bibr16-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11365-z"},{"key":"bibr17-25158414221108021","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2019.26235"},{"key":"bibr18-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13501"},{"key":"bibr19-25158414221108021","first-page":"257","volume":"17","author":"Brown MM","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"bibr20-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.11.1496"},{"key":"bibr21-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.5.758"},{"key":"bibr22-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.2.211"},{"key":"bibr23-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.11.1460"},{"key":"bibr24-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2008.562"},{"key":"bibr25-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3225"},{"key":"bibr26-25158414221108021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000353","volume":"4","author":"Jelin E","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"bibr27-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-018-0109-z"},{"key":"bibr28-25158414221108021","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0536-1"}],"container-title":["Therapeutic Advances in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414221108021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25158414221108021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414221108021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:40:09Z","timestamp":1777596009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25158414221108021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"alternative-id":["10.1177\/25158414221108021"],"URL":"https:\/\/doi.org\/10.1177\/25158414221108021","relation":{},"ISSN":["2515-8414","2515-8414"],"issn-type":[{"value":"2515-8414","type":"print"},{"value":"2515-8414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"25158414221108021"}}